CSF3 and breast carcinoma: The international guidelines are supported further by recent results from the GeparTrio trial, in which patients with breast cancer who received neoadjuvant TAC were given the following prophylactic treatments: the antibiotic ciprofloxacin (500 mg twice daily on days 5–14), non-pegylated G-CSF (5 μg kg–1 day–1 filgrastim or 150 μg m–2 day–1 lenograstim on days 5–10), pegfilgrastim (6 mg on day 2) or a combination of the pegfilgrastim and the ciprofloxacin schedules (von Minckwitz et al, 2008).